Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Precancerous Conditions 3Neuroblastoma 3Skin Neoplasms 2Prostatic Neoplasms 2Carcinoma, Basal Cell 2Adenomatous Polyposis Coli 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Non-melanoma Skin Cancer 1Keratosis, Actinic 1Gastritis, Atrophic 1Esophageal Neoplasms 1Colorectal Neoplasms 1Adenomatous Polyps 1

Interventions

Cisplatin 117Oxaliplatin 111Fluorouracil 100Capecitabine 90Docetaxel 69Leucovorin 60Irinotecan 57Paclitaxel 49S 1 (combination) 38pembrolizumab 35Trastuzumab 31Radiotherapy 25Bevacizumab 20Nivolumab 19Epirubicin 19titanium silicide 18Surgical Procedures, Operative 17Carboplatin 17Ramucirumab 16Cetuximab 15Gastrectomy 13apatinib 12Everolimus 12Gemcitabine 11Albumin-Bound Paclitaxel 10Neoadjuvant Therapy 8Folfox protocol 8Drug Therapy 8Chemotherapy, Adjuvant 8Radiation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Stomach Neoplasms × Eflornithine × Clear all
NCT02794428 2024-10-16

Chemoprevention of Gastric Carcinogenesis

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
91 enrolled 10 charts
Gastrointestinal

Gastritis, Atrophic, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡